Ratio de rendimiento sobre el capital contable (ROE)
desde 2005
Cálculo
Merck & Co. Inc., ROE, tendencias a largo plazocálculo
| ROE | = | 100 | × | Utilidad neta atribuible a Merck & Co., Inc.1 | ÷ | Capital contable total de Merck & Co., Inc.1 | |
|---|---|---|---|---|---|---|---|
| 31 dic 2024 | 36.96% | = | 100 | × | 17,117) | ÷ | 46,313) |
| 31 dic 2023 | 0.97% | = | 100 | × | 365) | ÷ | 37,581) |
| 31 dic 2022 | 31.57% | = | 100 | × | 14,519) | ÷ | 45,991) |
| 31 dic 2021 | 34.17% | = | 100 | × | 13,049) | ÷ | 38,184) |
| 31 dic 2020 | 27.91% | = | 100 | × | 7,067) | ÷ | 25,317) |
| 31 dic 2019 | 37.99% | = | 100 | × | 9,843) | ÷ | 25,907) |
| 31 dic 2018 | 23.30% | = | 100 | × | 6,220) | ÷ | 26,701) |
| 31 dic 2017 | 6.97% | = | 100 | × | 2,394) | ÷ | 34,336) |
| 31 dic 2016 | 9.78% | = | 100 | × | 3,920) | ÷ | 40,088) |
| 31 dic 2015 | 9.94% | = | 100 | × | 4,442) | ÷ | 44,676) |
| 31 dic 2014 | 24.50% | = | 100 | × | 11,920) | ÷ | 48,647) |
| 31 dic 2013 | 8.85% | = | 100 | × | 4,404) | ÷ | 49,765) |
| 31 dic 2012 | 11.63% | = | 100 | × | 6,168) | ÷ | 53,020) |
| 31 dic 2011 | 11.50% | = | 100 | × | 6,272) | ÷ | 54,517) |
| 31 dic 2010 | 1.58% | = | 100 | × | 861) | ÷ | 54,376) |
| 31 dic 2009 | 21.85% | = | 100 | × | 12,901) | ÷ | 59,058) |
| 31 dic 2008 | 41.63% | = | 100 | × | 7,808) | ÷ | 18,758) |
| 31 dic 2007 | 18.01% | = | 100 | × | 3,275) | ÷ | 18,185) |
| 31 dic 2006 | 25.25% | = | 100 | × | 4,434) | ÷ | 17,560) |
| 31 dic 2005 | 25.85% | = | 100 | × | 4,631) | ÷ | 17,917) |
Basado en los informes: 10-K (Fecha del informe: 2024-12-31), 10-K (Fecha del informe: 2023-12-31), 10-K (Fecha del informe: 2022-12-31), 10-K (Fecha del informe: 2021-12-31), 10-K (Fecha del informe: 2020-12-31), 10-K (Fecha del informe: 2019-12-31), 10-K (Fecha del informe: 2018-12-31), 10-K (Fecha del informe: 2017-12-31), 10-K (Fecha del informe: 2016-12-31), 10-K (Fecha del informe: 2015-12-31), 10-K (Fecha del informe: 2014-12-31), 10-K (Fecha del informe: 2013-12-31), 10-K (Fecha del informe: 2012-12-31), 10-K (Fecha del informe: 2011-12-31), 10-K (Fecha del informe: 2010-12-31), 10-K (Fecha del informe: 2009-12-31), 10-K (Fecha del informe: 2008-12-31), 10-K (Fecha del informe: 2007-12-31), 10-K (Fecha del informe: 2006-12-31), 10-K (Fecha del informe: 2005-12-31).
1 US$ en millones
Comparación con la competencia
Merck & Co. Inc., ROE, tendencias a largo plazo, comparación con los competidores
| Merck & Co. Inc. | AbbVie Inc. | Amgen Inc. | Bristol-Myers Squibb Co. | Danaher Corp. | Eli Lilly & Co. | Gilead Sciences Inc. | Johnson & Johnson | Pfizer Inc. | Regeneron Pharmaceuticals Inc. | Thermo Fisher Scientific Inc. | Vertex Pharmaceuticals Inc. | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 31 dic 2024 | 36.96% | 128.66% | 69.59% | -54.78% | 7.87% | 74.62% | 2.48% | 19.68% | 9.11% | 15.03% | 12.78% | -3.26% |
| 31 dic 2023 | 0.97% | 46.94% | 107.78% | 27.27% | 8.91% | 48.65% | 24.81% | 51.11% | 2.38% | 15.22% | 12.83% | 20.59% |
| 31 dic 2022 | 31.57% | 68.60% | 178.97% | 20.37% | 14.39% | 58.64% | 21.62% | 23.36% | 32.79% | 19.14% | 15.80% | 23.88% |
| 31 dic 2021 | 34.17% | 74.91% | 87.96% | 19.46% | 14.24% | 62.16% | 29.55% | 28.20% | 28.47% | 43.03% | 18.94% | 23.19% |
| 31 dic 2020 | 27.91% | 35.30% | 77.20% | -23.84% | 9.17% | 109.79% | 0.68% | 23.25% | 15.21% | 31.86% | 18.47% | 31.22% |
| 31 dic 2019 | 37.99% | — | 81.07% | 6.66% | 9.94% | 319.09% | 23.91% | 25.42% | 25.77% | 19.08% | 12.45% | 19.34% |
| 31 dic 2018 | 23.30% | — | 67.15% | 35.07% | 9.40% | 32.88% | 25.51% | 25.60% | 17.59% | 27.91% | 10.65% | 47.28% |
| 31 dic 2017 | 6.97% | 104.16% | 7.84% | 8.58% | 9.45% | -1.76% | 22.64% | 2.16% | 29.47% | 19.51% | 8.76% | 12.99% |
| 31 dic 2016 | 9.78% | 128.41% | 25.85% | 27.55% | 11.10% | 19.54% | 71.48% | 23.49% | 12.12% | 20.13% | 9.39% | -9.69% |
| 31 dic 2015 | 9.94% | 130.39% | 24.71% | 10.97% | 14.17% | 16.53% | 97.70% | 21.66% | 10.75% | 17.40% | 9.25% | -59.19% |
| 31 dic 2014 | 24.50% | 101.84% | 20.01% | 13.49% | 11.11% | 15.55% | 78.45% | 23.40% | 12.81% | 13.69% | 9.22% | -68.70% |
| 31 dic 2013 | 8.85% | 91.90% | 23.00% | 16.91% | 12.04% | 26.57% | 27.05% | 18.68% | 28.83% | 21.74% | 7.55% | -32.81% |
| 31 dic 2012 | 11.63% | 156.85% | 22.80% | 14.39% | 12.58% | 27.69% | 27.84% | 16.74% | 17.93% | 60.24% | 7.62% | -10.71% |
| 31 dic 2011 | 11.50% | — | 19.35% | 23.25% | 12.85% | 32.11% | 41.60% | 16.94% | 12.18% | -45.65% | 8.84% | 3.76% |
| 31 dic 2010 | 1.58% | — | 19.32% | 19.74% | 13.08% | 40.82% | 49.48% | 23.57% | 9.40% | -19.79% | 6.74% | -149.74% |
| 31 dic 2009 | 21.85% | — | 20.32% | 71.49% | 9.90% | 45.45% | 41.40% | 24.25% | 9.59% | -17.10% | 5.51% | -58.57% |
| 31 dic 2008 | 41.63% | — | 20.58% | 42.86% | 13.43% | -30.76% | 48.43% | 30.46% | 14.08% | -19.75% | 6.66% | -192.51% |
| 31 dic 2007 | 18.01% | — | 17.72% | 20.50% | 15.08% | 21.61% | 46.69% | 24.41% | 12.53% | -22.94% | 5.25% | -144.23% |
| 31 dic 2006 | 25.25% | — | 15.56% | 15.86% | 16.89% | 24.25% | -65.54% | 28.11% | 27.10% | -47.24% | 1.21% | -40.89% |
| 31 dic 2005 | 25.85% | — | 17.96% | 26.77% | 17.67% | 18.34% | 26.88% | 27.49% | 12.32% | -83.72% | 7.99% | -85.05% |
Basado en los informes: 10-K (Fecha del informe: 2024-12-31), 10-K (Fecha del informe: 2023-12-31), 10-K (Fecha del informe: 2022-12-31), 10-K (Fecha del informe: 2021-12-31), 10-K (Fecha del informe: 2020-12-31), 10-K (Fecha del informe: 2019-12-31), 10-K (Fecha del informe: 2018-12-31), 10-K (Fecha del informe: 2017-12-31), 10-K (Fecha del informe: 2016-12-31), 10-K (Fecha del informe: 2015-12-31), 10-K (Fecha del informe: 2014-12-31), 10-K (Fecha del informe: 2013-12-31), 10-K (Fecha del informe: 2012-12-31), 10-K (Fecha del informe: 2011-12-31), 10-K (Fecha del informe: 2010-12-31), 10-K (Fecha del informe: 2009-12-31), 10-K (Fecha del informe: 2008-12-31), 10-K (Fecha del informe: 2007-12-31), 10-K (Fecha del informe: 2006-12-31), 10-K (Fecha del informe: 2005-12-31).
Comparativa con el sector industrial: Productos farmacéuticos, biotecnología y ciencias de la vida
Merck & Co. Inc., ROE, tendencias a largo plazo, en comparación con el sector industrial: productos farmacéuticos, biotecnología y ciencias de la vida
| Merck & Co. Inc. | Productos farmacéuticos, biotecnología y ciencias de la vida | |
|---|---|---|
| 31 dic 2024 | 36.96% | 15.57% |
| 31 dic 2023 | 0.97% | 20.65% |
| 31 dic 2022 | 31.57% | 27.99% |
| 31 dic 2021 | 34.17% | 29.75% |
| 31 dic 2020 | 27.91% | 17.22% |
| 31 dic 2019 | 37.99% | 27.68% |
| 31 dic 2018 | 23.30% | 26.29% |
| 31 dic 2017 | 6.97% | 14.59% |
| 31 dic 2016 | 9.78% | 22.19% |
| 31 dic 2015 | 9.94% | 21.44% |
| 31 dic 2014 | 24.50% | 20.91% |
| 31 dic 2013 | 8.85% | 20.33% |
| 31 dic 2012 | 11.63% | 18.27% |
| 31 dic 2011 | 11.50% | 15.52% |
| 31 dic 2010 | 1.58% | 13.99% |
| 31 dic 2009 | 21.85% | 20.34% |
| 31 dic 2008 | 41.63% | 21.31% |
| 31 dic 2007 | 18.01% | 17.07% |
| 31 dic 2006 | 25.25% | 21.86% |
| 31 dic 2005 | 25.85% | 19.08% |
Basado en los informes: 10-K (Fecha del informe: 2024-12-31), 10-K (Fecha del informe: 2023-12-31), 10-K (Fecha del informe: 2022-12-31), 10-K (Fecha del informe: 2021-12-31), 10-K (Fecha del informe: 2020-12-31), 10-K (Fecha del informe: 2019-12-31), 10-K (Fecha del informe: 2018-12-31), 10-K (Fecha del informe: 2017-12-31), 10-K (Fecha del informe: 2016-12-31), 10-K (Fecha del informe: 2015-12-31), 10-K (Fecha del informe: 2014-12-31), 10-K (Fecha del informe: 2013-12-31), 10-K (Fecha del informe: 2012-12-31), 10-K (Fecha del informe: 2011-12-31), 10-K (Fecha del informe: 2010-12-31), 10-K (Fecha del informe: 2009-12-31), 10-K (Fecha del informe: 2008-12-31), 10-K (Fecha del informe: 2007-12-31), 10-K (Fecha del informe: 2006-12-31), 10-K (Fecha del informe: 2005-12-31).
Comparación con la industria: Atención médica
Merck & Co. Inc., ROE, tendencias a largo plazo, en comparación con la industria: atención médica
| Merck & Co. Inc. | Atención médica | |
|---|---|---|
| 31 dic 2024 | 36.96% | 15.74% |
| 31 dic 2023 | 0.97% | 19.40% |
| 31 dic 2022 | 31.57% | 24.82% |
| 31 dic 2021 | 34.17% | 25.44% |
| 31 dic 2020 | 27.91% | 16.70% |
| 31 dic 2019 | 37.99% | 23.30% |
| 31 dic 2018 | 23.30% | 21.27% |
| 31 dic 2017 | 6.97% | 13.77% |
| 31 dic 2016 | 9.78% | 18.53% |
| 31 dic 2015 | 9.94% | 18.52% |
| 31 dic 2014 | 24.50% | 19.17% |
| 31 dic 2013 | 8.85% | 18.81% |
| 31 dic 2012 | 11.63% | 18.20% |
| 31 dic 2011 | 11.50% | 15.90% |
| 31 dic 2010 | 1.58% | 14.85% |
| 31 dic 2009 | 21.85% | 20.14% |
| 31 dic 2008 | 41.63% | 20.29% |
| 31 dic 2007 | 18.01% | 17.87% |
| 31 dic 2006 | 25.25% | 20.49% |
| 31 dic 2005 | 25.85% | 18.28% |
Basado en los informes: 10-K (Fecha del informe: 2024-12-31), 10-K (Fecha del informe: 2023-12-31), 10-K (Fecha del informe: 2022-12-31), 10-K (Fecha del informe: 2021-12-31), 10-K (Fecha del informe: 2020-12-31), 10-K (Fecha del informe: 2019-12-31), 10-K (Fecha del informe: 2018-12-31), 10-K (Fecha del informe: 2017-12-31), 10-K (Fecha del informe: 2016-12-31), 10-K (Fecha del informe: 2015-12-31), 10-K (Fecha del informe: 2014-12-31), 10-K (Fecha del informe: 2013-12-31), 10-K (Fecha del informe: 2012-12-31), 10-K (Fecha del informe: 2011-12-31), 10-K (Fecha del informe: 2010-12-31), 10-K (Fecha del informe: 2009-12-31), 10-K (Fecha del informe: 2008-12-31), 10-K (Fecha del informe: 2007-12-31), 10-K (Fecha del informe: 2006-12-31), 10-K (Fecha del informe: 2005-12-31).